SCHEDULE 13G/A: BlackRock Amends Stake in Relay Therapeutics, Disclosing 8.8% Beneficial Ownership

BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting an 8.8% beneficial ownership stake in Relay Therapeutics, Inc. as of December 31, 2024.

Summary

• BlackRock, Inc. reported beneficial ownership of 14,674,262 shares of Common Stock in Relay Therapeutics, Inc.
• This aggregate amount represents 8.8% of the class of securities.
• BlackRock, Inc. holds sole voting power over 13,904,464 shares.
• BlackRock, Inc. holds sole dispositive power over 14,674,262 shares.
• No shared voting or shared dispositive power was reported.
• The filing is an Amendment No. 3 to Schedule 13G, indicating an update to a previously reported stake.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: This filing is a routine disclosure of beneficial ownership and does not contain performance or forward-looking statements, thus it is neutral in sentiment.

Industry Context

This filing is a standard disclosure by a large institutional asset manager, BlackRock, indicating its passive investment position in a publicly traded company within the biotechnology or pharmaceutical sector, Relay Therapeutics, Inc. Such filings are common and reflect portfolio management activities rather than specific industry trends.

Stakeholder Impact

• Indicates significant institutional investor interest or confidence in Relay Therapeutics, Inc. from BlackRock, one of the world's largest asset managers.

Key Dates

Keywords

BlackRock, Relay Therapeutics, Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing, passive investment